反应停联合E—CHOP方案治疗难治性复发型非霍奇金淋巴瘤23例

目的观察反应停联合E—CHOP方案治疗难治性复发型非霍奇金淋巴瘤（NHL）的临床疗效。方法将46例难治性复发型NHL患者均分为两组，对照组采用E—CHOP方案治疗，治疗组采用反应停联合E—CHOP方案治疗，以21d为1个周期，对完成4个周期以上者进行疗效评价及随访其1年生存率和2年生存率。结果治疗组23例中完全缓解（CR）11例，部分缓解（PR）6例，无变化（ND）4例，进展（PD）2例，总有效率为73．91％；对照组23例中CR6例，PR3例，ND8例，PD6例，总有效率为39．13％，两组比较有显著性差异。治疗组1年生存率和2年生存率分别为86．96％（20／23）和56．52％（13／23），对照组1年生存率和2年生存率分别为78．26％（18／23）和39．13％（9／23），较之对照组，治疗组1年生存率有增加趋势，但统计学比较无差异，而2年生存率两组比较有统计学差异（P〈0．05）。结论反应停联合E—CHOP方案治疗难治性复发型NHL疗效满意．值得临床推广。

Clinical Study of E-CHOP plus Thalidomide in Treatment of Advanced Non-Hodgkin's Lymphoma

Objective To evaluate the therapeutic effects and adverse reactions of combined thalidomide and E-CHOP in the treatment of advanced non-Hodgkin' s lymphoma(NHL).Methods 23 patients with advanced NHL received thalidomide and chemotherapy of E-CHOP, three weeks as one circle.The efficacy was evaluated after 4 circles.Results There were CR(11),PR(6),ND(4),PD(2).The overall efficacy rate was 73.91% .There was no difference in the one year survival rate of two groups.But there was significant difference in the two-year survival rate.Conclusion combined thalidomide with E-CHOP can gain the good therapeutic effect in advanced NHL.The side reactions can be well tolerated.